YBX3 and prostate adenocarcinoma: The results showed that YBX3 was differentially expressed in immune subtypes of cancers including BLCA (bladder urothelial carcinoma), CESC (cervical squamous cell carcinoma and endocervical adenocarcinoma), COAD, KIRC, KIRP, LGG, LIHC, LUAD, LUSC, PCPG (pheochromocytoma and paraganglioma), and PRAD (prostate adenocarcinoma), and the differences between the subgroups of each tumor mentioned above were also statistically significant, with P-value <0.05 (Supplementary Figure S1–1A).